Biomarker for COVID-19 risk
Researchers identified serum amyloid A (SAA) as a potential biomarker for COVID-19 risk, with higher levels associated with increased inflammation, clot abnormalities, and organ damage. This biomarker could help facilitate early identification of patients requiring aggressive management and monitoring.